Pronova Biopharma granted GMP certification in Denmark
The GMP certificate from the Danish Medicines Agency verifies compliance with the GMP guidelines. The GMP guidelines are intended to ensure that the active pharmaceutical substance manufactured has the quality and purity it is represented to possess. The Agency will, at Pronova BioPharma's request, conduct periodic inspections at the facility to ensure continued compliance.
"The GMP certificate marks another important milestone for the company's new manufacturing plant in Kalundborg. The remaining regulatory approvals are expected to be achieved early in 2010, in order for the first commercial shipments to take place in Q1" said Kjetil Olsen, senior vice president supply chain.
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.